News Nykode Therapeutics

Equities

VACC

NO0010714785

Real-time Oslo Bors Other stock markets 10:45:00 2024-05-08 am EDT			5-day change	1st Jan Change
13.61 ^NOK	0.00%		+1.80%	-36.40%

Apr. 19	Nykode Therapeutics Launches Phase 2 Clinical Trial for Cervical Cancer Vaccine	MT
Apr. 19	Nykode Therapeutics ASA Initiates Phase 2 Trial of VB10.16 in Second Line HPV16-Positive Cervical Cancer	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Nykode Therapeutics Launches Phase 2 Clinical Trial for Cervical Cancer Vaccine	Apr. 19	MT
Nykode Therapeutics : Remuneration Report 2023	Apr. 19	PU
Nykode Therapeutics ASA Initiates Phase 2 Trial of VB10.16 in Second Line HPV16-Positive Cervical Cancer	Apr. 19	CI
Nykode Therapeutics Announces Topline Conclusions Affirming Prolonged Clinical Benefits from Matured Survival Data in Phase 2 C-02 Trial in Advanced Cervical Cancer	Mar. 21	CI
Nykode Therapeutics ASA Announces Advances in the Inverse Vaccine Platform with the Potential to Treat Autoimmune Diseases	Mar. 19	CI
Transcript : Nykode Therapeutics AS, Q4 2023 Earnings Call, Feb 28, 2024	Feb. 28
Nykode Therapeutics AS Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 28	CI
Nykode Therapeutics AS Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Transcript : Nykode Therapeutics AS Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 03:45 PM	Jan. 10
Nykode Therapeutics Announces Expansion of Oncology Pipeline Aiming to Reduce the Burden of Colorectal Cancer	Dec. 14	CI
Nykode Therapeutics AS Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 15	CI
Transcript : Nykode Therapeutics AS, Q3 2023 Earnings Call, Nov 15, 2023	Nov. 15
Nykode Therapeutics - Mandatory notification of acquisition of shares by primary insider	23-10-27	AQ
Nykode Therapeutics AS announced that it has received NOK 505.29474 million in funding	23-10-24	CI
Nykode Therapeutics AS announced that it expects to receive NOK 329.999987 million in funding	23-10-23	CI
Nykode Therapeutics Kicks off Early-stage Trial of Head, Neck Skin Cancer Treatment	23-09-29	MT
Nykode Therapeutics ASA Initiates Phase 1/2a Trial of VB10.16 in First Line HPV16-Positive Head and Neck Cancer	23-09-28	CI
Transcript : Nykode Therapeutics AS - Analyst/Investor Day	23-09-20
Nykode Therapeutics ASA Announces Advances in Clinical Pipeline and Research	23-09-20	CI
Nykode Therapeutics Wins US FDA Nod for Mid-stage Study of Cervical Cancer Combo	23-09-05	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Nykode Therapeutics

Equities

VACC

NO0010714785

Summary

Filters